EDGE

Discussion in 'Stocks' started by SoesWasBetter, Mar 28, 2018.

  1. Write it down

    Biotech stocks are not stocks , they are options.

    Trade accordingly
     
    zdreg likes this.
  2. All stocks...are not stocks, they are options....atleast in terms of risks. (if i understand your analogy correctly)

    For most people, they are better off just buying the broad market instead of playing or toying or dabbling or trading or gambling or investing in individual stocks and companies and random misc tickers and instruments.

    And you can Take that to the Bank.
    Put som Sauce on dat thang,
    2018 ET. o_O
     
    Last edited: Mar 28, 2018
  3. dealmaker

    dealmaker

    Tempest emerges with $70M to take IDO inhibitor into clinic
    Tempest Therapeutics raised $70 million in a series B round to advance a trio of immuno-oncology programs into clinical trials. The funds will propel its lead candidate, an IDO inhibitor dubbed TPST-8844, into the clinic within the next year, with at least two programs to follow. “We are extremely excited to debut Tempest and look forward to rapidly advancing a superior IDO inhibitor into the clinic as the first of four new programs,” said CEO Tom Dubensky.(FierceBiotech)